BRCA1 and BRCA2 Gene Mutations and Lung Cancer Risk: A Meta-Analysis

被引：14

作者：

Lee, Yen-Chien ^{[1
,2
]}

Lee, Yang-Cheng ^{[3
]}

Li, Chung-Yi ^{[4
,5
,6
]}

Lee, Yen-Ling ^{[1
]}

Chen, Bae-Ling ^{[7
]}

机构：

[1] Minist Hlth & Welf, Dept Oncol, Tainan Hosp, Tainan 700, Taiwan

[2] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 700, Taiwan

[3] Tainan Municipal Hosp, Tainan 700, Taiwan

[4] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 700, Taiwan

[5] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung 404, Taiwan

[6] Asia Univ, Coll Med & Hlth Sci, Dept Healthcare Adm, Taichung 413, Taiwan

[7] Natl Taichung Univ Sci & Technol, Coll Intelligence, Taichung 404, Taiwan

来源：

MEDICINA-LITHUANIA | 2020年 / 56卷 / 05期

关键词：

lung cancer; BRCA1; BRCA2; meta-analysis; RELATIVES; BREAST; SMOKING; WOMEN;

D O I：

10.3390/medicina56050212

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background and objective: BRCA1 and BRCA2 are associated with many cancer types in addition to hereditary breast and ovarian cancers. However, their relation to lung cancer remains to be explored. Materials and Methods: Observation studies were systematically reviewed to explore the association of BRCA1 or BRCA2 with lung cancer. PubMed, MEDLINE [EBSCOhost], and relevant articles published up to 7 January 2020 were searched. Odd ratio (OR), standardized morbidity rate (SMR), and cancer-specific standardized incidence ratios (SIRs) were pooled together as relative risk (RR) estimates (95% confidence interval [CI], 0.66-1.40). Results: Thirteen studies were included for analysis. Results showed that the RR of BRCA2 is 0.76 (95% CI, 0.48-1.19), the overall RR is 0.96 (95% CI, 0.66-1.40), and that of BRCA1 is 0.66 (95% CI, 0.41-1.05), indicating that it was not associated with lung cancer. Conclusion: With the limitation of the retrospective study design and severe heterogeneity, these results inform clinicians and relevant families that BRCA1 and BRCA2 mutation carriers have no increased risk of lung cancer.

引用

页数：11

共 26 条

[1] Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer [J].

Annunziato, Stefano ;

de Ruiter, Julian R. ;

Henneman, Linda ;

Brambillasca, Chiara S. ;

Lutz, Catrin ;

Vaillant, Francois ;

Ferrante, Federica ;

Drenth, Anne Paulien ;

van der Burg, Eline ;

Siteur, Bjorn ;

van Gerwen, Bas ;

de Bruijn, Roebi ;

van Miltenburg, Martine H. ;

Huijbers, Ivo J. ;

van de Ven, Marieke ;

Visvader, Jane E. ;

Lindeman, Geoffrey J. ;

Wessels, Lodewyk F. A. ;

Jonkers, Jos .

NATURE COMMUNICATIONS, 2019, 10 (1)

[2]

Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310

[3]

Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365

[4] Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites [J].

Digennaro, M. ;

Sambiasi, D. ;

Tommasi, S. ;

Pilato, B. ;

Diotaiuti, S. ;

Kardhashi, A. ;

Trojano, G. ;

Tufaro, A. ;

Paradiso, A. V. .

HEREDITARY CANCER IN CLINICAL PRACTICE, 2017, 15

[5] Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations [J].

Dite, G. S. ;

Whittemore, A. S. ;

Knight, J. A. ;

John, E. M. ;

Milne, R. L. ;

Andrulis, I. L. ;

Southey, M. C. ;

McCredie, M. R. E. ;

Giles, G. G. ;

Miron, A. ;

Phipps, A. I. ;

West, D. W. ;

Hopper, J. L. .

BRITISH JOURNAL OF CANCER, 2010, 103 (07) :1103-1108

[6] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].

FORD, D ;

EASTON, DF ;

BISHOP, DT ;

NAROD, SA ;

GOLDGAR, DE ;

HAITES, N ;

MILNER, B ;

ALLAN, L ;

PONDER, BAJ ;

PETO, J ;

SMITH, S ;

STRATTON, M ;

LENOIR, GM ;

FEUNTEUN, J ;

LYNCH, H ;

ARASON, A ;

BARKARDOTTIR, R ;

EGILSSON, V ;

BLACK, DM ;

KELSELL, D ;

SPURR, N ;

DEVILEE, P ;

CORNELISSE, CJ ;

VARSEN, H ;

BIRCH, JM ;

SKOLNICK, M ;

SANTIBANEZKOREF, MS ;

TEARE, D ;

STEEL, M ;

PORTER, D ;

COHEN, BB ;

CAROTHERS, A ;

SMYTH, E ;

WEBER, B ;

NEWBOLD, B ;

BOEHNKE, M ;

COLLINS, FS ;

CANNONALBRIGHT, LA ;

GOLDGAR, D .

LANCET, 1994, 343 (8899) :692-695

[7] The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials [J].

Guo, Xiao Xia ;

Wu, Hong Li ;

Shia, Hong Yun ;

Su, Lei ;

Zhang, Xi .

CANCER MANAGEMENT AND RESEARCH, 2018, 10 :2553-2562

[8] Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers [J].

Johannsson, O ;

Loman, N ;

Möller, T ;

Kristoffersson, U ;

Borg, Å ;

Olsson, H .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (08) :1248-1257

[9] Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort [J].

Julian-Reynier, Claire ;

Resseguier, Noemie ;

Bouhnik, Anne-Deborah ;

Eisinger, Francois ;

Lasset, Christine ;

Fourme, Emmanuelle ;

Nogues, Catherine .

GENETICS IN MEDICINE, 2015, 17 (02) :117-124

[10] The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans [J].

Kim, Hakyoung ;

Choi, Doo Ho ;

Park, Won ;

Im, Young-Hyuck ;

Ahn, Jin Seok ;

Park, Yeon Hee ;

Nam, Seok Jin ;

Kim, Seok Won ;

Lee, Jeong Eon ;

Yu, Jong Hwan ;

Lee, Se Kyung ;

Jung, Boo Yeon .

HEREDITARY CANCER IN CLINICAL PRACTICE, 2019, 17 (1)

← 1 2 3 →